With over ten years in venture capital, Selina co-founded and serves as Director of Skyline Galaxy Capital, an early-stage VC firm backing some of Singapore’s most groundbreaking biotech therapeutics innovators.
Her portfolio centers on companies pioneering transformative technologies – from immunotherapies and cell-based treatments for infection-associated cancers to AI platforms designed to accelerate drug discovery, reduce risk, and enhance development efficiency. Her investments include a series of leading cell therapy companies in Singapore, alongside ventures advancing novel oncology therapeutics, neurodegenerative disease treatments, and next-generation drug discovery platforms.
From inception through scale-up, Selina has played an active role in guiding these companies’ strategic development – from early fundraising and clinical planning to navigating regulatory milestones and driving international expansion. Several of her portfolio companies have now matured into established biotech players, with two progressing towards IPO.
With her deep expertise in biotech venture building and a proven track record of cultivating high-growth therapeutics companies, Selina offers a unique perspective on how startups can grow sustainably while positioning for long-term success.